Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2026)
Bicycle Therapeutics (BCYC) posted EBITDA Margin of 7382.41% for Q1 2026, down 14228.3% on a QoQ basis from 51.52% in Q4 2025, and down 667875.0% year-over-year from N/an in Q1 2025.
Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' EBITDA Margin history runs 9 years deep, the most recent figure standing at 7382.41% for Q1 2026.
- Quarterly EBITDA Margin fell 667875.0% year-over-year to 7382.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 381.67% (up 58389.0% YoY) and the FY2025 annual result came in at 340.38%, up 25458.0% from the prior year.
- EBITDA Margin was 7382.41% for Q1 2026 at Bicycle Therapeutics, down from 51.52% in the prior quarter.
- Across five years, EBITDA Margin topped out at 51.52% in Q4 2025 and bottomed at 7382.41% in Q1 2026.
- A 5-year average of 1321.26% and a median of 709.4% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2025 — EBITDA Margin jumped 182723 bps — and 2026, when it tumbled 667875 bps.
- Bicycle Therapeutics' EBITDA Margin stood at 383.46% in 2022, then plunged by 165 bps to 1017.35% in 2023, then slumped by 79 bps to 1824.78% in 2024, then jumped by 97 bps to 51.52% in 2025, then sank by 14228 bps to 7382.41% in 2026.
- Business Quant data shows BCYC's EBITDA Margin at 7382.41% in Q1 2026, 51.52% in Q4 2025, and 558.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | -7,382.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,382.41% |
| Dec 31, 2025 | -51.52% |
| Sep 30, 2025 | -558.64% |
| Jun 30, 2025 | -2,965.82% |
| Mar 31, 2025 | -703.66% |
| Dec 31, 2024 | -1,824.78% |
| Sep 30, 2024 | -2,385.87% |
| Jun 30, 2024 | -498.31% |
| Mar 31, 2024 | -304.96% |
| Dec 31, 2023 | -1,017.35% |
| Sep 30, 2023 | -949.12% |
| Jun 30, 2023 | -378.27% |
| Mar 31, 2023 | -853.82% |
| Dec 31, 2022 | -383.46% |
| Sep 30, 2022 | -978.91% |
| Jun 30, 2022 | -515.09% |
| Mar 31, 2022 | -709.40% |
| Dec 31, 2021 | -1,126.50% |
| Sep 30, 2021 | -329.89% |
| Jun 30, 2021 | -967.90% |